ES2761340T3 - Formulaciones de liberación mantenida para la administración de proteínas al ojo y procedimientos de preparación de las mismas - Google Patents
Formulaciones de liberación mantenida para la administración de proteínas al ojo y procedimientos de preparación de las mismas Download PDFInfo
- Publication number
- ES2761340T3 ES2761340T3 ES12829655T ES12829655T ES2761340T3 ES 2761340 T3 ES2761340 T3 ES 2761340T3 ES 12829655 T ES12829655 T ES 12829655T ES 12829655 T ES12829655 T ES 12829655T ES 2761340 T3 ES2761340 T3 ES 2761340T3
- Authority
- ES
- Spain
- Prior art keywords
- formulation
- plga
- atec
- lactide
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Marine Sciences & Fisheries (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161495672P | 2011-06-10 | 2011-06-10 | |
| PCT/US2012/041950 WO2013036309A2 (en) | 2011-06-10 | 2012-06-11 | Sustained release formulations for delivery of proteins to the eye and methods of preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2761340T3 true ES2761340T3 (es) | 2020-05-19 |
Family
ID=47832748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12829655T Active ES2761340T3 (es) | 2011-06-10 | 2012-06-11 | Formulaciones de liberación mantenida para la administración de proteínas al ojo y procedimientos de preparación de las mismas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9814773B2 (enExample) |
| EP (1) | EP2717914B1 (enExample) |
| JP (1) | JP6339011B2 (enExample) |
| KR (1) | KR20140060274A (enExample) |
| CN (1) | CN103945865B (enExample) |
| AU (1) | AU2012304909B2 (enExample) |
| BR (1) | BR112013031685B1 (enExample) |
| CA (1) | CA2838289C (enExample) |
| CY (1) | CY1122771T1 (enExample) |
| DK (1) | DK2717914T3 (enExample) |
| ES (1) | ES2761340T3 (enExample) |
| HR (1) | HRP20192276T1 (enExample) |
| HU (1) | HUE047737T2 (enExample) |
| IN (1) | IN2013MN02384A (enExample) |
| LT (1) | LT2717914T (enExample) |
| MX (1) | MX359119B (enExample) |
| PL (1) | PL2717914T3 (enExample) |
| PT (1) | PT2717914T (enExample) |
| RS (1) | RS60051B1 (enExample) |
| SI (1) | SI2717914T1 (enExample) |
| SM (1) | SMT202000021T1 (enExample) |
| WO (1) | WO2013036309A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6530744B2 (ja) * | 2013-05-24 | 2019-06-12 | アイコン バイオサイエンス インコーポレイテッド | 白内障手術後の炎症における徐放性デキサメタゾンの使用 |
| KR102312186B1 (ko) * | 2014-05-08 | 2021-10-14 | 판옵테스 파르마 게스.엠.베.하. | 안 질환 및 장애 치료용 화합물 |
| ES2969514T3 (es) * | 2015-03-18 | 2024-05-21 | Santen Pharmaceutical Co Ltd | Composición farmacéutica de liberación sostenida |
| CA2991015A1 (en) * | 2015-07-01 | 2017-01-05 | Santen Pharmaceutical Co., Ltd. | Depot preparation containing citric acid ester |
| WO2017024027A1 (en) * | 2015-08-03 | 2017-02-09 | Tolmar International Limited | Liquid polymer delivery system for extended administration of drugs |
| PT3352735T (pt) | 2015-09-21 | 2023-10-30 | Teva Pharmaceuticals Int Gmbh | Formulações de olanzapina de libertação sustentada |
| AU2018238136A1 (en) | 2017-03-20 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
| KR101957599B1 (ko) | 2017-10-23 | 2019-03-13 | 김상현 | 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지 |
| WO2019157198A2 (en) | 2018-02-09 | 2019-08-15 | Icon Bioscience, Inc. | Systems, kits and methods for loading and delivering a small volume dose from a syringe |
| EP3787609A4 (en) | 2018-05-01 | 2022-01-05 | Chibi, Inc. | Eye drop formulation and method for sustained delivery of medicament to the retina |
| KR20210003877A (ko) | 2018-05-01 | 2021-01-12 | 치비 인코포레이티드 | 약제를 눈에 비침습적으로 지속 전달하기 위한 액체 데포 |
| EP4153214A4 (en) | 2020-05-22 | 2024-06-26 | Trustees of Boston University | METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASE |
| EP4277661A1 (en) | 2021-01-18 | 2023-11-22 | Anton Frenkel | Pharmaceutical dosage form |
| US20240277654A1 (en) | 2021-07-06 | 2024-08-22 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658432B1 (fr) * | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation. |
| EP1299048A4 (en) * | 2000-06-28 | 2005-09-28 | Atul J Shukla | BIODEGRADABLE VEHICLES AND SYSTEMS FOR DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES |
| TWI353854B (en) * | 2002-06-25 | 2011-12-11 | Alza Corp | Short duration depot formulations |
| US20040001889A1 (en) * | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| CA2527664A1 (en) * | 2003-05-30 | 2004-12-16 | Alza Corporation | Implantable elastomeric depot compositions, uses thereof and method of manufacturing |
| US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| BRPI0516830A (pt) * | 2004-10-01 | 2008-09-23 | Ramscor Inc | composições de droga de liberação sustentada convenientemente implantáveis |
| BRPI0516308A2 (pt) * | 2004-10-04 | 2010-06-15 | Qlt Usa Inc | composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| WO2010105093A2 (en) * | 2009-03-12 | 2010-09-16 | Delpor, Inc. | Implantable device for long-term delivery of drugs |
| EP2269663B1 (en) * | 2009-07-03 | 2018-03-07 | Armbruster Biotechnology GmbH | Bone graft and biocomposite |
-
2012
- 2012-06-11 IN IN2384MUN2013 patent/IN2013MN02384A/en unknown
- 2012-06-11 ES ES12829655T patent/ES2761340T3/es active Active
- 2012-06-11 JP JP2014514933A patent/JP6339011B2/ja active Active
- 2012-06-11 MX MX2013014461A patent/MX359119B/es active IP Right Grant
- 2012-06-11 LT LTEP12829655.5T patent/LT2717914T/lt unknown
- 2012-06-11 SM SM20200021T patent/SMT202000021T1/it unknown
- 2012-06-11 BR BR112013031685-3A patent/BR112013031685B1/pt active IP Right Grant
- 2012-06-11 WO PCT/US2012/041950 patent/WO2013036309A2/en not_active Ceased
- 2012-06-11 PT PT128296555T patent/PT2717914T/pt unknown
- 2012-06-11 RS RS20191574A patent/RS60051B1/sr unknown
- 2012-06-11 SI SI201231706T patent/SI2717914T1/sl unknown
- 2012-06-11 HU HUE12829655A patent/HUE047737T2/hu unknown
- 2012-06-11 EP EP12829655.5A patent/EP2717914B1/en active Active
- 2012-06-11 US US14/124,631 patent/US9814773B2/en active Active
- 2012-06-11 HR HRP20192276TT patent/HRP20192276T1/hr unknown
- 2012-06-11 DK DK12829655.5T patent/DK2717914T3/da active
- 2012-06-11 PL PL12829655T patent/PL2717914T3/pl unknown
- 2012-06-11 CA CA2838289A patent/CA2838289C/en active Active
- 2012-06-11 CN CN201280028816.4A patent/CN103945865B/zh active Active
- 2012-06-11 AU AU2012304909A patent/AU2012304909B2/en active Active
- 2012-06-11 KR KR1020147000443A patent/KR20140060274A/ko not_active Withdrawn
-
2020
- 2020-01-17 CY CY20201100042T patent/CY1122771T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2717914T3 (pl) | 2020-05-18 |
| HRP20192276T1 (hr) | 2020-05-15 |
| AU2012304909A1 (en) | 2013-12-19 |
| SI2717914T1 (sl) | 2020-07-31 |
| RS60051B1 (sr) | 2020-04-30 |
| EP2717914A4 (en) | 2015-05-13 |
| BR112013031685B1 (pt) | 2021-04-06 |
| CN103945865B (zh) | 2016-10-26 |
| EP2717914A2 (en) | 2014-04-16 |
| EP2717914B1 (en) | 2019-10-30 |
| WO2013036309A2 (en) | 2013-03-14 |
| CN103945865A (zh) | 2014-07-23 |
| DK2717914T3 (da) | 2020-01-20 |
| MX359119B (es) | 2018-09-14 |
| CA2838289C (en) | 2019-09-10 |
| MX2013014461A (es) | 2014-05-14 |
| BR112013031685A2 (pt) | 2017-02-07 |
| HUE047737T2 (hu) | 2020-05-28 |
| LT2717914T (lt) | 2020-03-25 |
| IN2013MN02384A (enExample) | 2015-06-12 |
| JP2014516087A (ja) | 2014-07-07 |
| PT2717914T (pt) | 2019-12-18 |
| KR20140060274A (ko) | 2014-05-19 |
| CY1122771T1 (el) | 2021-05-05 |
| US20140140992A1 (en) | 2014-05-22 |
| SMT202000021T1 (it) | 2020-03-13 |
| AU2012304909B2 (en) | 2017-06-08 |
| CA2838289A1 (en) | 2013-03-14 |
| JP6339011B2 (ja) | 2018-06-06 |
| US9814773B2 (en) | 2017-11-14 |
| WO2013036309A3 (en) | 2013-05-10 |
| NZ619707A (en) | 2015-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2761340T3 (es) | Formulaciones de liberación mantenida para la administración de proteínas al ojo y procedimientos de preparación de las mismas | |
| Kang-Mieler et al. | Advances in ocular drug delivery systems | |
| CN101060831B (zh) | 可方便植入的缓释药物组合物 | |
| EP2142189B1 (en) | Methods and compositions for intraocular administration to treat ocular conditions | |
| Iyer et al. | Long-acting intraocular Delivery strategies for biological therapy of age-related macular degeneration | |
| JP6980671B2 (ja) | 眼科用組成物 | |
| MXPA06012439A (es) | Implantes intraoculares de liberacion sostenida que comprenden macromoleculas y metodos relacionados. | |
| US20160130321A1 (en) | Use of a vegf antagonist in treating macular edema | |
| CN104812397A (zh) | 用于持续释放蛋白质的生物可降解的药物递送系统 | |
| Ugurlu et al. | Transscleral delivery of bevacizumab-loaded chitosan nanoparticles | |
| US20200375889A1 (en) | Bioerodible polyester polymer implants and related methods of use | |
| ES2616296T3 (es) | Micropartículas de liberación controlada | |
| US20220054407A1 (en) | Ocular compositions | |
| NZ619707B2 (en) | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | |
| HK1196081A (en) | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | |
| HK1196081B (en) | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | |
| ES3006986T3 (en) | Biodegradable compositions and implants | |
| Kimura et al. | Biodegradable systems |